Psychotropic Medication Review and PRN Order Deficiencies
Summary
The facility failed to ensure that residents receiving psychotropic medications had gradual dose reductions attempted when indicated and that behavioral interventions were used unless clinically contraindicated. The report identified six residents affected by these issues, including residents receiving lorazepam, buspirone, Ambien, Seroquel, and Zyprexa. Facility staff and leadership acknowledged during interviews that psychotropic medications should have appropriate review, that PRN psychotropic medications should have 14-day limits, and that rationales should be documented when a gradual dose reduction was not attempted or when a PRN order was extended. For one resident with COPD and moderate cognitive impairment, the record showed an Ativan 0.5 mg PRN order for anxiety written for 30 days, and the medication had not been administered during the reviewed month. The facility’s policy stated PRN psychotropic medications are limited to 14 days unless the prescriber documents a rationale for extending use and includes the duration. The record did not contain a documented rationale for extending the PRN lorazepam order beyond 14 days. For another resident with paranoid schizophrenia, major depressive disorder, anxiety disorder, and PTSD, the consultant pharmacist recommended gradual dose reductions for buspirone and Ambien, but the physician marked the recommendations as disagree and did not provide a rationale. For a resident with schizoaffective disorder and severe cognitive impairment, the pharmacist recommended reducing Seroquel, but the physician again disagreed and documented only that the resident was stable. The report also identified a resident with severe cognitive impairment and dementia who had a PRN lorazepam order written as indefinite per Hospice, with no 14-day end date, and another resident with Alzheimer’s disease, psychosis, and agitation whose Seroquel order lacked a documented rationale and response for recommendations related to the diagnosis and gradual dose reduction review.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release August 26, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.